D.E. Shaw & Co
LRMR icon

D.E. Shaw & Co’s Larimar Therapeutics LRMR Stock Holding History

D.E. Shaw & Co’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-575,624
Closed -$2.59M – 5068
2026
Q1 		$2.59M Buy
575,624
+138,225
+32% +$552K ﹤0.01% 2715
2025
Q4 		$1.67M Buy
+437,399
New +$1.7M ﹤0.01% 3193
2024
Q4 		– Sell
-16,122
Closed -$106K – 4660
2024
Q3 		$106K Buy
+16,122
New +$130K ﹤0.01% 4245
2019
Q4 		– Sell
-20,322
Closed -$180K – 4078
2019
Q3 		$180K Buy
20,322
+11,890
+141% +$130K ﹤0.01% 3642
2019
Q2 		$121K Sell
8,432
-2,552
-23% -$68K ﹤0.01% 3532
2019
Q1 		$361K Sell
10,984
-1,436
-12% -$73.6K ﹤0.01% 3139
2018
Q4 		$738K Sell
12,420
-9,488
-43% -$937K ﹤0.01% 2861
2018
Q3 		$3.07M Sell
21,908
-7,105
-24% -$862K ﹤0.01% 1902
2018
Q2 		$3.56M Sell
29,013
-3,779
-12% -$321K ﹤0.01% 1777
2018
Q1 		$2.93M Sell
32,792
-3,251
-9% -$276K ﹤0.01% 1765
2017
Q4 		$2M Sell
36,043
-3,343
-8% -$151K ﹤0.01% 2143
2017
Q3 		$1.66M Buy
39,386
+2,407
+7% +$100K ﹤0.01% 2161
2017
Q2 		$1.56M Sell
36,979
-5,328
-13% -$272K ﹤0.01% 2135
2017
Q1 		$2.37M Buy
42,307
+4,604
+12% +$229K ﹤0.01% 1733
2016
Q4 		$1.44M Buy
37,703
+6,513
+21% +$264K ﹤0.01% 2245
2016
Q3 		$1.24M Sell
31,190
-3,835
-11% -$174K ﹤0.01% 2258
2016
Q2 		$2.52M Buy
35,025
+7,069
+25% +$559K ﹤0.01% 1761
2016
Q1 		$2.24M Buy
+27,956
New +$2.21M ﹤0.01% 1803
2015
Q3 		– Sell
-731
Closed -$304K – 3819
2015
Q2 		$304K Buy
+731
New +$306K ﹤0.01% 3411

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

D.E. Shaw & Co's LRMR Position: Q2 2026 in Review

D.E. Shaw & Co sold out of Larimar Therapeutics (LRMR) in Q2 2026, closing a stake of 575,624 shares — an estimated $2.59M sold.

D.E. Shaw & Co first reported a position in LRMR in Q2 2015 and held it in 19 quarters. The position peaked at $3.56M in Q2 2018. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • D.E. Shaw & Co reported no remaining Larimar Therapeutics position as of Q2 2026 after selling out during the quarter.
  • D.E. Shaw & Co sold 575,624 Larimar Therapeutics shares in Q2 2026, an estimated $2.59M.
  • D.E. Shaw & Co first reported a position in Larimar Therapeutics in Q2 2015 and held it in 19 quarters.
  • D.E. Shaw & Co's Larimar Therapeutics position peaked at $3.56M in Q2 2018.
  • 163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.